

Special Issue

The Neurotoxicity of Biomedicines

Message from the Guest Editor

Neurotoxicity arises when excessive exposure to natural or synthetic substances detrimentally affects the functioning of the peripheral and/or central nervous system. Biomedicines or ethnomedicines may be neurotoxic by a number of molecular mechanisms, for example, via the induction of redox stress, and may trigger or contribute to neurodegeneration and neuronal death. In this Special Issue entitled 'The Neurotoxicity of Biomedicines' we are requesting manuscripts or review articles that cover agents that initiate or propagate neurotoxicity. This includes the neurotoxicity of biomedicines and ethnomedicines as pure or partially pure extracts or fractions, and the neurotoxicity of synthetic medicines. The evaluation of neurotoxicity will consider agent application to cell lines or administration to animals, or the neurotoxicity of an agent evidenced from human studies. The collation of novel research studies and review articles covering neurotoxicity will produce a useful resource of cutting-edge research in this field to help evaluate the next generation of biomedicines.

Guest Editor

Dr. Wayne Carter

Clinical Toxicology, School of Medicine, The University of Nottingham, Nottingham NG7 2RD, UK

Deadline for manuscript submissions

closed (31 January 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/137364

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).